385 related articles for article (PubMed ID: 12738363)
1. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
2. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
[TBL] [Abstract][Full Text] [Related]
4. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
5. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
6. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
7. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
8. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Parkhurst MR; Fitzgerald EB; Southwood S; Sette A; Rosenberg SA; Kawakami Y
Cancer Res; 1998 Nov; 58(21):4895-901. PubMed ID: 9809996
[TBL] [Abstract][Full Text] [Related]
9. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
[TBL] [Abstract][Full Text] [Related]
10. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
11. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
[TBL] [Abstract][Full Text] [Related]
12. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
[TBL] [Abstract][Full Text] [Related]
14. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
15. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
16. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
17. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
18. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
19. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
[TBL] [Abstract][Full Text] [Related]
20. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
